Physician profile
Steven E Layton
NPI 1053487454
$6,471.81
in general payments reported to CMS, 2019-2025
36 companies · $888 in 2025
The $888 reported for 2025 was more than what 78% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,108 · 2022: $1,303 · 2023: $911 · 2024: $1,262 · 2025: $888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,040 · Education: $20.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,039.62 |
| Education | $20.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,009.68 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $966.71 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $609.93 | 2021-2024 | Repatha, Otezla, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $586.16 | 2021-2025 | Jardiance |
| Abbvie INC. | $571.76 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $507.74 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $270.30 | 2021-2024 | |
| Lilly USA, LLC | $178.56 | 2021-2025 | Mounjaro, Kisunla, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $172.21 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.09 | 2021-2022 | |
| Esperion Therapeutics, INC. | $137.47 | 2021 | |
| Phathom Pharmaceuticals, INC. | $128.92 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $126.74 | 2021 | |
| Paratek Pharmaceuticals, INC. | $113.24 | 2021 | |
| Eisai INC. | $92.96 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $87.30 | 2023 | Freestyle Libre 2, Freestyle Libre 3 |
| Jazz Pharmaceuticals INC. | $75.43 | 2021 | |
| Pfizer INC. | $72.04 | 2023-2024 | |
| Electromed, INC. | $72.01 | 2021-2022 | |
| Almatica Pharma LLC | $68.64 | 2022-2024 | Loreev Xr |
| Exact Sciences Corporation | $62.23 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $57.61 | 2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $56.54 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $56.29 | 2021-2024 | Livalo |
| Dexcom, INC. | $43.46 | 2022 | |
| Mallinckrodt Hospital Products INC. | $30.87 | 2021-2022 | |
| Medtronic, INC. | $22.38 | 2024 | Intellis Adaptivestim |
| Biohaven Pharmaceutical Holding Company LTD. | $19.99 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.36 | 2021 | |
| Baxter Healthcare | $17.78 | 2022 | |
| Axsome Therapeutics, INC. | $16.65 | 2025 | Auvelity |
| Ultragenyx Pharmaceutical INC. | $16.16 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.64 | 2021 | |
| Grifols USA, LLC | $13.17 | 2021 | |
| Merck Sharp & Dohme LLC | $12.15 | 2021 | |
| Vistapharm, INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Layton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.